Cataract surgery is the single most common surgical procedure performed in the United States annually. Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery.

We have developed a new, proprietary lens that will increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery via our proprietary design, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, our newly-developed Omega Implant is well positioned to become the new standard lens for cataract surgery.